Ascletis, Inc.

76 articles about Ascletis, Inc.

• Ascletis Received IND Approval for its NASH Drug

  8/27/2019

  ASC40, an orally bioavailable, first-in-class inhibitor of fatty acid synthase, is currently in a global Phase 2 trial in NASH of which the first patient was dosed in late April, 2019 in the USA.

• 3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

  4/30/2019

  3-V Biosciences, Inc. and Ascletis Pharma Inc. announced that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN inhibitor TVB-2640 in patients with non-alcoholic steatohepatitis.

• Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease

  4/15/2019

  Ascletis Pharma Inc. announces that according to the official notifications from Zhejiang Provincial Medical Insurance Bureau, Zhejiang Provincial Department of Finance and Zhejiang Provincial Health Committee, the "Basic Medical Insurance -- Reimbursement-by-disease for outpatients with Hepatitis C" program will be launched in Zhejiang Province.

• Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing

  2/13/2019

  Ascletis Pharma Inc. and 3-V Biosciences, Inc. jointly announce that Ascletis, through its subsidiary, and 3-V Biosciences have entered into an exclusive license agreement for 3-V Biosciences' FASN inhibitor TVB-2640, a first-in-class, Phase 2-ready drug candidate for non-alcoholic steatohepatitis, in Greater China.

• Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer

  11/11/2018

  Ascletis Pharma Inc. announces today that Dr. Lindi Tan joins Ascletis as Chief Financial Officer.

• Ascletis to Present Phase II / III Clinical Study for Its All-oral HCV Treatment at the 69th Annual meeting of AASLD

  11/6/2018

  Ascletis Pharma Inc. announces today that a phase II / III clinical study of its all-oral HCV treatment (RDV/DNV Regimen) has been selected by AASLD's Scientific Program Committee as a Poster Presentation.

• 

  Innovent Biologics Plans Hong Kong IPO to Raise $423 Million, Despite Global Downturn

  10/15/2018

  China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.

• Ascletis Appoints Mr. Joshua Zhongbao Ling as VP Finance

  8/30/2018

  Ascletis Pharma Inc. announced today that Mr. Joshua Zhongbao Ling joined Ascletis as Vice President of Finance. Mr. Ling will be responsible for the corporate finance management.

• Ascletis' Ravidasvir Recommended by WHO HCV Guidelines

  8/6/2018

  Ascletis Pharma Inc. (1672.HK) announced today Ravidasvir is recommended by the World Health Organization (WHO) Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection (July 2018) as a future pan-genotypic direct-acting antivirals agent (DAA). Ascletis received the acceptance letter for Ravidasvir new drug application (NDA) from the China Food and Drug Administration (CFDA) on August 1.

• 

  China’s Ascletis Debuted: Stocks Flat

  8/1/2018

  Chinese biotech company Ascletis Pharma debuted on the Hong Kong stock exchange, rising as much as 6.4 percent, but ending the day where it started.

• Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

  8/1/2018

  Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA).

• Ascletis Filed NDA for Its All-oral HCV Treatment

  7/31/2018

  The company expects to receive feedback from the China Food and Drug Administration (CFDA) within five business days.

• Ganovo (R) Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association

  7/30/2018

  The awarded paper won the highest scientific merits out of 577 conference papers submitted this year

• 

  Investment Bankers Leave Firms for Roles in Hong Kong Biotech Companies

  7/9/2018

  More and more pharma companies follow the trend of planning initial public offerings on the Hong Kong Stock Exchange. Another trend following this path is the number of prominent investment bankers who have left their firms for biotech companies in the former British colony.

• WuXi STA First CDMO to Support the Approval of an Innovative Drug in China Through the "MAH" Pilot

  6/14/2018

  WuXi STA enables Ascletis to receive NDA Approval from China FDA for Ganovo (R)

• Ascletis Receives NDA Approval from China FDA for Ganovo

  6/12/2018

  Ascletis announced that China Food and Drug Administration (CFDA) has approved its Category 1 new drug, Ganovo (also known as Danoprevir or ASC08), for the treatment of viral hepatitis C.

• 

  Two Chinese Pharma Companies, WuXi AppTec and Ascletis Pharma, List IPOs on Asian Exchanges

  5/8/2018

  Shares of Chinese pharmaceutical and medical device company WuXi AppTec were a hot commodity Tuesday as the company made its debut on the Shanghai Stock Exchange. Another Chinese company, Ascletis Pharma, also chose a new stock listing.

• Ascletis Plans $100M C Round; Then Hong Kong IPO

  1/22/2018

  The company will use the money to fund clinical trials and develop a marketing operation.

• Medivir Licenses Exclusive Rights To MIV-802 For Greater China To Ascletis

  8/18/2017

• Ascletis, Inc. Publishes Interim Data Of Phase II Study In Taiwan For Its Interferon-Free HCV Regimen

  6/21/2016